Zurück zu Projekte

19072.1 IP-LS

19072.1 IP-LS

Zusammenfassung

Development of neuroprotective molecules for the treatment of Amyotrophic lateral sclerosis (ALS)

Weitere Texte

Abstract

We have recently identified, using a drug-screening platform, a number of molecules that stimulate the activity of astrocytes, a type of glial cells that supports neuronal metabolism. These drugs, which improve neuronal survival and activity, are of particular interest for the treatment of neurodegenerative diseases. Most promising compounds are tested in a mouse model of ALS, as well as cognition/memory. The most effective candidates - whether neuroprotective or cognitive enhancers - will be patented and will represent the core of our Start-up pipeline

Beteiligte

Sylvain Lengacher

Wirtschaftspartner

sylengach@gliapharm.com

Gliapharm SA Sylvain Lengacher Ch. des Mines 9 1202 Geneva GE CH

Pierre Magistretti

Kontaktperson

pierre.magistretti@epfl.ch

EPFL Pierre Magistretti Station 19 1015 Lausanne VD CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2016-06-30
Enddatum
2018-11-30
Bewilligte Gesamtkosten
CHF 313717.00
Sektion
60 Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • T490 Biotechnology 100.0%